Nebulised 3% Hypertonic Saline Versus 0.9% Saline for Treating Patients Hospitalized With Acute Bronchiolitis
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Bronchiolitis is an acute viral infection of the lower respiratory tract. It is most commonly
caused by respiratory syncytial virus (RSV). Only supportive therapy, including suctioning
nasal secretions, water-electrolyte balance maintenance, and oxygen supplementation when
needed, is recommended. The inhalation of 3% hypertonic saline is not recommended in
bronchiolitis management. However, a recently published meta-analysis revealed that the
inhalation of hypertonic saline can reduce the risk of hospitalisation for outpatients with
bronchiolitis, while resulting in a shorter length of hospital stay and reduced severity of
respiratory distress for inpatients, although the evidence is of low certainty.
The aim of the study is to assess the efficacy of nebulised hypertonic saline for the
treatment of children hospitalised with bronchiolitis.